mechanism of resistance, clinical significance, and laboratory detection of hVISA and VISA 7 infections are not conclusive, making it difficult to apply research findings to clinical situations. 8
Introduction 11
Methicillin-resistant Staphylococcus aureus (MRSA) is the most commonly encountered bacteria 12 in hospitals and community settings 1 and is associated with invasive infections ranging in severity 13 from mild to fatal. 2 Vancomycin is considered the standard treatment for empiric and definitive 14 serious MRSA infections. was reported in 1997 from Japan.
9,10 The first hVISA isolate, designated Mu3, was identified in 27 Japan one year earlier from a patient with MRSA pneumonia unresponsive to vancomycin. 9 Since 28 then, hVISA and VISA cases have been reported in the United States, United Kingdom, China, 29 Australia, Turkey, France, Belgium, Germany, Italy, Brazil, and South Korea.
11
The true 30 prevalence of hVISA is unknown, and estimates vary widely because of non-standardized 31 detection methodologies or absence of routine hVISA screening, variation in interpretation, 32 geographical location, clinical setting, and differing patient populations. [12] [13] [14] [15] [16] [17] [18] [19] Reported rates of 33 hVISA throughout the world range from 0 to 73.7%. 16 
38
Only 14 of the 1,498 (0.93%) MRSA isolates were identified as VISA. There was no apparent 39 pattern of increasing prevalence over the three time periods for VISA isolates. An increase in 40 hVISA was also described in a similar retrospective study from Turkey of 1.6% in 1998 to 36% 41 in 2001. 20 Because clonality was not evaluated in either study, the increase in prevalence may 42 have reflected clonal spread rather than true prevalence. Prevalence may have been 43 underestimated because the isolates were stored for prolonged periods in glycopeptide-free media, 44 which may result in a loss of resistance. 21 Two surveillance studies conducted in 2009 and 2011 45 in over 40 U.S. medical centers determined rates of antimicrobial resistance among S. aureus 46 isolates collected from patients with infections.
22, 23 The rates of hVISA among MRSA isolates in 47 2011 were higher than in 2009 (1.2% vs. 0.4%, P = 0.003). 22 Of note, strains of VISA were not 48 detected. 22, 23 While the current prevalence of VISA is low, these organisms may become more 49 common in the future. Data suggests that heteroresistance is a precursor to VISA, therefore the 50 suspected increase in prevalence of hVISA may predict more VISA infections. 17, 19, 26 Consequently, several screening methods have been developed, such as 81 glycopeptide resistance detection (GRD), marcromethod E-test (MET) and brain heart infusion 82 (BHI) screen agar plates ( Table 2) . 27 Evidence suggests that hVISA and VISA arise during continued or sub-optimal exposure to 113 vancomycin. 7, 33 The proposed mechanism is selective pressure by vancomycin resulting in the 114 development of rare vancomycin-resistant clones that progress to hVISA and, with continued-115 exposure, to a uniform population of VISA clones. 5, 9 These isolates have significant differences 116 in cell physiology, including morphologic changes and genetic alterations. Strains of hVISA and 117 VISA are characterized by thicker cell walls that correlate with increased vancomycin MICs. 34 
118
Cell wall thickening impairs intracellular penetration of vancomycin rendering it ineffective. 5, 34 
119
In addition, hVISA and VISA are associated with slower growth rates than fully susceptible 120 strains, which may contribute to persistent and recurrent infections. 35 Other mechanisms of 121 resistance include alterations in transcriptional and metabolic genes and loss-of-function mutations 122 that disturb critical cell wall biosynthesis. 11 The accessory gene regulator (agr) operon directs 123 many critical virulence pathways, particularly the production of exotoxins.
11 In hVISA and VISA 124 strains, agr function is reduced, favoring the development of vancomycin resistance and 125 potentially promoting biofilm production that ultimately enhances the survival of hVISA and 126 VISA. heterogeneity cannot be excluded. Another study evaluated 559 MRSA isolates and found an 141 increased incidence of hVISA when the vancomycin MIC shifted from 1 to 2 μg/mL. 41 The 142 incidence of hVISA was nearly 40% in isolates with an MIC of 2 μg/mL, supporting the results of 143 other studies that suggest the proportion of hVISA isolates are directly related to increases in 144 vancomycin MIC. 6, 15, 23, 41 Increases in vancomycin MICs are hospital specific and perhaps caused 145 by clonal outbreaks. However, this highlights the trends of vancomycin tolerance, which may be 146 caused by overuse of vancomycin, sub-therapeutic vancomycin concentrations, high bacterial load, 147 or slow vancomycin bactericidal activity. 3, 42 Both hVISA and VISA have been identified in hospital and community strains of MRSA and in 150 MSSA. 16 The findings of studies that evaluated clinical predictors and outcomes of hVISA 151 infections are inconsistent. This may be attributed to the considerable heterogeneity of these 152 studies, including differences in study design, clinical definitions, selection of isolates (initial 153 isolate, final isolate, or random selection), patient populations, and testing methodologies. 154
Commonly reported associations with hVISA infections include vancomycin treatment failure and 155 high-inoculum MRSA infections (e.g., bacteremia, infective endocarditis, osteomyelitis, deep 156 abscesses, and prosthetic device infections). 6, 7, 14, 33, 43, 44 Other potential predictors of hVISA and 157 VISA infections are prior MRSA infection or colonization (previous 3 months), previous 158 vancomycin exposure (prior 6 months), initial low serum vancomycin trough levels (< 10 µg/mL), 159 persistent bacteremia (≥ 7 days), and presence of indwelling devices (Table 2) . 7,8,12,14,44,45 46 
160
Patients with hVISA infections tend to experience prolonged clinical courses, suboptimal response 162 to vancomycin therapy, and prolonged hospital stays. [6] [7] [8] 14, 33, 42, 44 One retrospective case-control 163 study compared the clinical features and outcomes of hVISA bacteremia (n = 27) and MRSA 164 bacteremia (n = 223).
14 Compared with MRSA bacteremia, patients with hVISA infections had 165 significantly more days of bacteremia (median duration, 12 days vs. 2 days, respectively; P = 166 0.005) and significantly higher rates of endocarditis (18.5% vs. 3.6%, respectively; P = 0.007) and 167 osteomyelitis (25.9% vs. 7.2%, respectively; P = 0.006).
14 Of note, patients in the hVISA group 168 had significantly more prosthetic/implant devices (e.g., artificial heart valves, pacemakers, or 169 orthopedic implants) and surgical site infections (in the previous month) at baseline, which may 170 have attributed to poorer outcomes. In a small case series, glycopeptide treatment failure, (defined 171 as a positive S. aureus blood culture after  7 days of glycopeptide therapy or a sterile site culture 172 positive for S. aureus after  21 days of glycopeptide therapy) occurred in 19 of 25 (76%) patients 173 with hVISA infections (bacteremia, endocarditis, osteomyelitis, or septic arthritis). results. 6 Study investigators concluded that rates of vancomycin treatment failure were 11 times 178 higher for a patient with hVISA BSI (50/61, 82%) than VS-MRSA BSI (20/61, 32.8%; P <0.001). 179
Patients with hVISA BSI were also more likely than patients with VS-MRSA BSI to have 180 persistent bacteremia (59% vs. 21.3%, respectively; P <0.001), infection recurrence at 60 days 181 (25.5% vs. 1.9%, respectively; P < 0.001), and longer hospital length of stay (median in days, 24 182 vs. 16, respectively; P = 0.022). While differences in 30-day MRSA infection-related mortality 183 and all-cause 30-day mortality were not observed between the hVISA BSI group and VS-MRSA 184 BSI group (21.3% vs. 9.8%; P = 0.081 and 24.6% vs. 11.5%; P = 0.076, respectively). Similarly, 185 no other studies have been powered to detect a significant difference in mortality between hVISA 186 and non-hVISA infections. A recent systematic review and meta-analysis evaluated 30-day 187 mortality from eight comparative hVISA studies. 18 After combining the data, 30-day mortality 188 between hVISA and VSSA infections were similar (OR, 1.18; 95% CI, 0.81-1.74). 18 However, 189 these findings may be limited by the variability in definitions used and the predominately 190 retrospective designs of the original studies. While the lack of association between hVISA and 191 mortality can be partly explained by strain characteristics (e.g., decreased virulence) and host 192 immune responses, sufficiently sized studies are needed to accurately determine if such an 193 association exits. 47 
195
Infections caused by VISA may also lead to recurrent infections, prolonged fevers and bacteremia, 196 vancomycin treatment failure, and increased hospital stay. 7, 12, 33, 44 In a single-center, retrospective 197 study, 6 patients with VISA had a significantly longer duration of bacteremia compared to 22 with 198 hVISA (12.1 ± 13.1 days vs. 3.3 ± 3.9 days, respectively; P = 0.001). 43 Significant differences in 199 mortality between VISA and hVISA were not observed. However, rates of attributable mortality 200 between hVISA and VSSA (n = 215) were similar (9.1% vs. Daptomycin is a potential treatment option for hVISA and VISA infections and, although it does 216 have activity against MRSA, previous vancomycin exposure can result in some degree of cross-217 resistance to daptomycin.
48,49
Several studies have noted an in vitro association between 218 increasing vancomycin MICs and increasing daptomycin non-susceptibility. [48] [49] [50] The highest rate 219 of daptomycin non-susceptibility was reported in a study evaluating 47 Australian hVISA and 220 VISA isolates never exposed to daptomycin. 50 The investigators noted daptomycin non-221 susceptibly in 15% of hVISA and 38% of VISA strains. 50 Because bactericidal activity with 222 daptomycin is concentration dependent, higher doses may be necessary to treat hVISA and VISA 223 infections with elevated daptomycin MICs, high inoculum infections (e.g., endocarditis), and 224 infection sites characterized by poor antimicrobial penetration.
51 High-dose daptomycin may 225 prevent the selection or development of isolates with reduced susceptibility to daptomycin and 226 subsequent treatment failure. de-escalation (10 mg/kg/day for 4 days followed by 6 mg/kg/day for 4 days) regimens compared 231 to that of the standard (6 mg/kg/day for 8 days) and dose escalation (6 mg/kg/day for 4 days 232 followed by 10 mg/kg/day for 4 days) regimens. 51 With respect to hVISA, the dose de-escalation 233 regimen had a significantly increased killing effect on the hVISA strain compared to the dose 234 escalation regimen (P < 0.024). 51 The investigators concluded that these daptomycin dosing 235 approaches may lead to a faster cure of bacteremia in vivo and prevent the emergence of 236 daptomycin non-susceptibility. 51 However, no in vivo studies evaluating de-escalation dosing and 237 the appropriate duration of high-dose daptomycin have been published. The role of high-dose 238 daptomycin alone in patients with hVISA or VISA infections is unclear. Until more evidence is 239 available, caution is required when considering daptomycin in patients who may be at risk for 240 hVISA or VISA infections (e.g. high-bacterial load infections, vancomycin failure). The 241 determination of daptomycin susceptibility in these patients may also guide therapeutic decision 242 making. 243
Linezolid 245
The role of linezolid for the treatment of invasive hVISA and VISA infections is also in question. 246
Successful use of linezolid alone or in combination with other antimicrobial agents has been 247 described in several case reports of vancomycin heteroresistant and intermediate MRSA 248
endocarditis and bacteremias after vancomycin failure and in some cases after daptomycin 249 failure. 8, [52] [53] [54] [55] In one case report, a 60 year old male with an automatic implantable cardioverter-250 defibrillator (AICD) presented with bacteremia and endocarditis initially caused by MRSA which 251 later developed into hVISA, then daptomycin non-susceptible VISA after exposure to vancomycin 252 and daptomycin. 55 The patient initially received 6 weeks of vancomycin (trough concentrations 253 between ≥ 15 µg/mL and ≤ 21 µg/mL), followed by approximately 25 days of daptomycin (6 254 mg/kg every 48 hours, renal dose adjusted). During therapy with daptomycin the defibrillator 255 generator and leads were removed however, the patient was persistently bacteremic and febrile. Ceftaroline has potent in vitro bactericidal activity against MRSA including hVISA, VISA, and 267 daptomycin non-susceptible (DNS) MRSA strains. 57 The use of ceftaroline in the treatment of 268 invasive infections (e.g., endocarditis, bacteremia, osteomyelitis) caused by hVISA, VISA, and 269 DNS MRSA is supported by data from in vivo animal studies and human case reports. [58] [59] [60] [61] In a 270 recent case series report, a patient with DNS VISA bacteremia and endocarditis was successfully 271 treated with 6 weeks of ceftaroline. The patient initially received and failed vancomycin therapy. 62 
272
Blood cultures cleared within 48 hours of switching to daptomycin (6 mg/kg/day). However, 273 subsequent blood cultures were positive and revealed DNS VISA. Daptomycin was discontinued, 274 and ceftaroline (600 mg IV every 8 hours) was initiated. While on ceftaroline, blood cultures 275 cleared within 48 hours and remained sterile. In vitro pharmacokinetic/pharmacodynamic studies 276 reported enhanced ceftaroline activity against hVISA, VISA, and DNS MRSA as vancomycin and 277 daptomycin susceptibilities decreased, which have been referred to as the "seesaw effect".
58-60 278
While further study is needed, ceftaroline appears to be a safe and effective alternative in the 279 treatment of invasive hVISA, VISA, and DNS MRSA infections given its bactericidal activity, 280 favorable safety profile, and emerging data. 281
282

Combination therapy 283
The combination of vancomycin or daptomycin and a beta-lactam antimicrobial has also been 284 studied for treatment of hVISA and VISA infections. Beta-lactams that have been evaluated for 285 synergistic activity with vancomycin or daptomycin include ceftaroline, cefazolin, and 286 piperacillin-tazobactam. [63] [64] [65] [66] In vitro and clinical case report data evaluating the combination of 287 high-dose daptomycin (10 mg/kg/day) and trimethoprim/sulfamethoxazole also appear promising 288 for the treatment of hVISA, VISA, and DNS MRSA infections. 67, 68 In vitro studies have 289 demonstrated improved kill rates with these antimicrobial combinations. [63] [64] [65] Investigators 290
hypothesize that beta-lactam exposure may influence vancomycin-cell wall interactions to 291 improve vancomycin activity, although further investigation is warranted. 
